GeoJunxion convenes an Extraordinary General Shareholders Meeting (EGM)
Capelle aan den IJssel, The Netherlands 26 October 2023 - GeoJunxion publishes the convocation and meeting agenda for an Extraordinary General Shareholders Meeting (EGM) to be held on 12 December 2023.
The meeting materials and the convocation including the agenda are available on the GeoJunxion website.
INVITATION TO ATTEND AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF GEOJUNXION N.V.
GeoJunxion N.V. (the ‘Company’) invites its shareholders to attend an Extraordinary General Meeting of Shareholders (‘EGM’) to be held on Tuesday 12 December 2023 at 10:00 hrs. (CET) at the offices of the Company at the address Rivium Quadrant 75, 9th floor, 2909 LC, Capelle aan den IJssel, the Netherlands. Registration for admission shall commence at 09:00 hrs. (CET) and shall end at 10:00 hrs. (CET).
|2.||Approval of the Share Sale (as defined in the explanatory notes to the agenda) pursuant to Section 2:107a of the Dutch Civil Code (Burgerlijk Wetboek) (the ‘DCC’) (voting item)||VOTING|
|3.||Dissolution of GeoJunxion N.V. in accordance with Section 2:19 DCC, with effect as of the moment immediately after execution of the Deed of Transfer (as defined in the explanatory notes to the agenda) and subject to Completion (as defined in the explanatory notes to the agenda) (voting item)||VOTING|
|4.||Appointment of Stichting JTC Liquidator (as defined in the explanatory notes to the agenda), as liquidator (vereffenaar) of the Company without supervision of the Supervisory Board of the Company and determination that the liquidator shall be reimbursed for its reasonable salary and costs in so far and to the extent that such salary and costs are covered and compensated by Road Runner B.V., with effect as of the moment immediately after execution of the Deed of Transfer and subject to Completion (voting item)||VOTING|
|5.||Appointment of GeoJunxion B.V. as custodian (bewaarder) of the books, records and other data carriers of the Company in accordance with Section 2:24 DCC, with effect as of the moment immediately after execution of the Deed of Transfer and subject to Completion (voting item)||VOTING|
|6.||Acceptance of the voluntary resignation of, and granting of full and final discharge to, all resigning members of the Management Board of the Company, with effect as of the moment immediately after execution of the Deed of Transfer and subject to Completion (voting item)||VOTING|
|7.||Acceptance of the voluntary resignation of, and granting of full and final discharge to, all resigning members of the Supervisory Board of the Company, with effect as of the moment immediately after execution of the Deed of Transfer and subject to Completion (voting item)||VOTING|
|8.||Approval of the Distribution (as defined in the explanatory notes to the agenda) as soon as possible after receipt of the proceeds from the Proposed Transaction, with effect as of the moment immediately after execution of the Deed of Transfer and subject to Completion (voting item)||VOTING|
The agenda and explanatory notes thereto, are available on the Company’s website. The aforementioned documents are also available at the offices of the Company, Rivium Quadrant 75, 2909 LC, Capelle aan den IJssel, Tel. +31 (10) 8851200, Fax +31 (10) 8851240, the Netherlands) and at ING Bank N.V. (Issuer Services, location TRC 02.039, Foppingadreef 7, 1102 BD Amsterdam, the Netherlands or e-mail: email@example.com), and will be available at the meeting.
Record Date and registration
Those shareholders who are registered in one of the (sub)registers designated by the Management Board, on Tuesday 14 November 2023 at 17:00 (CET), following processing of all settlements per this date (the ‘Record Date’), have the right to attend the EGM and exercise their voting rights in accordance with the number of shares held on the Record Date. The designated (sub)registers are the administration records of the intermediaries in the meaning of the Securities Giro Act (Wet Giraal Effectenverkeer) and the shareholders register of the Company.
Shareholders of electronic securities, who wish to attend the EGM or to give a proxy (with voting instructions), should register electronically with Evote by ING (via https://evote.ingwb.com), or through their intermediaries at which their shares are administered, in the period starting Wednesday 15 November 2023 up to and including Tuesday 5 December 2023 17:00 (CET).
No later than Wednesday 6 December 2023 at 13:00 (CET), the intermediaries have to provide ING (via https://evote.ingwb.com) with an electronic statement that includes details of the shareholder concerned and its number of shares held on the Record Date, for those shareholders that applied for registration. The receipt of the registration, supplied by ING via the relevant intermediary, will serve as confirmation to attend the EGM.
Shareholders registered in the Company’s shareholders’ register who wish to attend the EGM or to give a proxy (with voting instructions), should register either by mail (ING, Issuer Services, location 2 TRC02.039, Foppingadreef 7, 1102 BD Amsterdam, the Netherlands, or by e-mail: firstname.lastname@example.org), in the period starting Wednesday 15 November 2023 up to and including Tuesday 5 December 2023 17:00 (CET). The confirmation of registration will serve as confirmation to attend the EGM.
Voting and attending by proxy
Shareholders who wish to grant a proxy to Mr. Cees Molenaar, Chairman of the Supervisory Board, or his substitute, each of them severally (the ‘Chairman’), or wish to authorize a third party to attend the meeting on their behalf, may do so in the manner described below, provided that they have applied for the meeting in time in the manner described above.
Electronic proxy to the Chairman of the Supervisory Board
Shareholders of electronic securities may grant an electronic proxy including a voting instruction to the Chairman of the Supervisory Board in the period starting Wednesday 15 November 2023 up to and including Tuesday 5 December 2023 17:00 (CET). This is possible via https://evote.ingwb.com or using the Proxy Voting form available on the Company’s website.
Written proxy to the Chairman of the Supervisory Board or a third party
A form for a written proxy to third parties or the Chairman is available on the Company’s website or can be asked for at ING (telephone +31 (0)20 5762716; email: email@example.com). The completed proxy forms must be sent to ING, either by mail (ING, Issuer Services, location TRC02.039, Foppingadreef 7, 1102 BD Amsterdam, the Netherlands) or by e-mail (firstname.lastname@example.org) and must be received by ING in the period starting Wednesday 15 November 2023 up to and including Tuesday 5 December 2023 17:00 (CET).
Registration and identification at the meeting
Registration for admission to the EGM will take place from 09:00 hrs. (CET) until 10:00 hrs. (CET). After this time registration is no longer possible. Persons entitled to attend the meeting may be asked for identification prior to being admitted by means of a valid identity document, such as a passport, identity card or driver’s license.
Questions regarding the agenda items
Until Thursday 7 December 2023, registered shareholders may submit written questions about the items on the agenda, by email to email@example.com. These questions will be answered ultimately during the EGM. Questions about all agenda items can also be asked during the EGM.
Number of issued and outstanding shares
On the date of the notice for this EGM, the number of issued and outstanding shares in the capital of the Company is 4,246,178 ordinary shares, each representing one vote.
Capelle aan den IJssel, the Netherlands, 26 October 2023
The Management Board and the Supervisory Board of GeoJunxion N.V.
This is a public announcement by GeoJunxion N.V., pursuant to article 17, paragraph 1 of the European Market Abuse Regulation (596/2014). This public announcement does not constitute an offer, or solicitation of an offer, to buy or offer securities in GeoJunxion N.V.
GeoJunxion NV Head Office - Rivium Quadrant 75 - 2909 LC Capelle aan den IJssel - The Netherlands - Phone: 31 (0)10 885 1200 - Fax: 31 (0)10 885 1230 - www.geojunxion.com
- 20231026 - Registration and Proxy Voting GeoJunxion N.V. EGM (ENG version) - final
- 20231026 - EGM Agenda and explanatory notes (ENG Version)
- 20231026 - EGM Convocation (ENG version)
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful
Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release
At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t